Condition

Thymoma Type B3 (3)

Thymic Carcinoma (2)

Melanoma (1)

Metastatic Thymic Carcinoma (1)

Ovarian Cancer (1)

Pancreas Cancer (1)

Sarcoma (1)

Thymoma Type B2 (1)

Overall Status

Recruiting (2)

Completed (1)

Sign in for free

Phase

phase 2 (3)

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC (1)

Istituto Clinico Humanitas (1)

MedSIR (1)

Collaborator

ETOP IBCSG Partners Foundation (1)

Merck Sharp & Dohme Corp. (1)

Intervention

lenvatinib 10 mg (1)

nivolumab (1)

pembrolizumab (1)

regorafenib (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (3)

thymoma type b3

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Pancreas Cancer, Ovarian Cancer, Melanoma Trial in Rozzano (Regorafenib)

Completed

Pancreas Cancer
+6 more

Regorafenib

Rozzano, Milan, Italy

Istituto Clinico Humanitas

Sep 9, 2022

Thymoma Type B3, Thymic Carcinoma Trial in Worldwide (Nivolumab)

Recruiting

Thymoma Type B3
Thymic Carcinoma

Nivolumab

Brussel, Belgium
+19 more

Jul 1, 2022

Metastatic Thymic Carcinoma, Thymoma Type B3 Trial in France, Italy, Spain (Pembrolizumab, Lenvatinib 10 mg)

Recruiting

Metastatic Thymic Carcinoma
Thymoma Type B3

Pembrolizumab
Lenvatinib 10 mg

Bordeaux, France
+9 more

Feb 7, 2022